Skip to main content
Evidence: BGrowth HormoneRecovery & Healing

Hexarelin: Benefits, Dosage & FDA Status

Hexarelin (HEX)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

FDA Status

Not FDA-approved — research compound (cardioprotective signals investigated)

Typical Dose

100 mcg, 1–2 times daily (subcutaneous)

Evidence Grade

BLimited clinical + robust preclinical evidence

Half-Life

~70 minutes

Routes of Administration

subcutaneous

First Synthesized

1990s

Clinics Indexed

41 providers have offered Hexarelin in our tracked directory.

Mechanism of Action

Synthetic hexapeptide GHS-R1a agonist; also binds CD36 in cardiac tissue, the basis of its cardioprotective signal in preclinical models.

Key Reported Benefits

Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.

Reported Side Effects

  • Cortisol/prolactin elevation
  • Tachyphylaxis (diminishing GH response)

Contraindications

  • Active malignancy
  • Pregnancy

Commonly Stacked With

Regulatory & Safety Context

FDA status: Not FDA-approved — research compound (cardioprotective signals investigated)

This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.

See state-by-state legality: US peptide legality by state →

References

Selected primary literature on Hexarelin. Full PubMed records linked. Additional citations are available on request.

  1. PubMed PMID 9665963
  2. PubMed PMID 16959903

Last reviewed: 2026-04-30

← Back to all peptides